
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Scout Clinical, a provider of comprehensive clinical trial patient services, has announced the results of their rare disease clinical trial patient focus group. Conducted in partnership with ICON plc, the initiative sought to amplify the voices of those whose lives are touched by rare diseases.
The information from these focus groups addresses the gap between the experiences and perceptions of patients and the participation support services provided to them during clinical trials. The series found:






